Compositions and methods for treating articular cartilage disorders

Abstract

A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) is provided. The method comprises increasing the amount of IGF-I at the diseased or injured articular site to a therapeutically effective level that is capable of maintenance and / or regeneration of cartilage, which is beneficial to the long-term treatment of osteoarthritis and trauma-related injuries to cartilage tissues. In one embodiment of the invention, single doses of at least 0.01 mg of pharmaceutically effective IGF-I are administered intermittently such that the duration of time off of therapy is greater than the time on therapy, more preferably with a frequency of administration of about once per week or less.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 10 / 199,449, filed Jul. 19, 2002; which is a continuation of U.S. application Ser. No. 09 / 285,554, filed Apr. 2, 1999; which claims the benefit of U.S. Provisional Application No. 60 / 080,683, filed Apr. 3, 1998, the contents of which are hereby incorporated herein in their entirety by reference.FIELD OF THE INVENTION [0002] This invention relates to methods for long-term treatment of mammalian articular cartilage disorders. These methods use therapeutic agents that preserve existing cartilage tissues or stimulate regeneration of cartilage to counteract the degenerative effects of the cartilage disorder or injury. BACKGROUND OF THE INVENTION [0003] Articular cartilage plays an essential role in the movement of mammalian joints. While synovial fluid within the joint cavity serves as a lubricant, the articular cartilage provides a superior smooth surface between adjacent bones,...

AI Technical Summary

Benefits of technology

[0013] A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) as the therapeutic agent is provided. The method of the present invention comprises increasing the total amount of IGF-I present at the site of the articular disorder or injury to a therapeutically effective level that enables maintenance and / or regeneration of cartilage. Increases in the amount of IGF-I at the affected articular site may be obtained via administration of a pharmaceutical composition comprising a therapeutically effective amount of IGF-I. Alternatively, or additionally, the level of naturally produced IGF-I may be regulated by gene therapy or by disruption of IGF-I binding to IGF-I binding proteins, whose binding to IGF-I decreases availability of free IGF-I. The present invention can be used in treating osteoarthritis and trauma-related injuries, wherein cartilage of joints is damaged, by promoting maintenance and / or regeneration of cartilage.

Problems solved by technology

Damage to the articular surface can disrupt this equilibrium, such that degradation exceeds the ability of chondrocytes to synthesize macromolecules necessary for repair of the cartilage tissues.

This disequilibrium results in loss of extracellular matrix or alteration of the material properties of the cartilage tissue.

Moreover, with trauma-related injuries, chondrocytes do not regenerate and are incapable of repairing focal defects or cartilage tears.

The range of motion for ajoint sustaining such an injury can be severely affected.

When left untreated, continued excessive degradation of proteoglycans and collagens by proteases ultimately leads to total loss of cartilage and ebumation of bone.

Historically, treatment of osteoarthritis and articular cartilage injuries has been limited to pain relief, reduction of joint loading, physical therapy, and orthopedic surgery, all of which are aimed at symptomatic relief rather than treatment of the underlying pathologic disorder.

Results of this study showed that intra-articular administration of IGF-I alone was ineffective in treating osteoarthritis, as cartilage in treated animals was not different from cartilage in untreated animals.

Images